441 related articles for article (PubMed ID: 27614333)
1. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival.
Abugharib A; Jackson WC; Tumati V; Dess RT; Lee JY; Zhao SG; Soliman M; Zumsteg ZS; Mehra R; Feng FY; Morgan TM; Desai N; Spratt DE
J Urol; 2017 Mar; 197(3 Pt 1):662-668. PubMed ID: 27614333
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy.
Lee LW; McBain CA; Swindell R; Wylie JP; Cowan RA; Logue JP
Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):517-22. PubMed ID: 15630843
[TBL] [Abstract][Full Text] [Related]
3. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
4. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer.
Katz MS; Zelefsky MJ; Venkatraman ES; Fuks Z; Hummer A; Leibel SA
J Clin Oncol; 2003 Feb; 21(3):483-9. PubMed ID: 12560439
[TBL] [Abstract][Full Text] [Related]
5. Significance of early prostate-specific antigen values after salvage radiotherapy in recurrent prostate cancer patients treated with surgery.
Chang JH; Park W; Park JS; Pyo H; Huh SJ; Choi HY; Lee HM; Jeon SS; Seo SI
Int J Urol; 2015 Jan; 22(1):82-7. PubMed ID: 25208624
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
[TBL] [Abstract][Full Text] [Related]
8. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features.
Hwang WL; Tendulkar RD; Niemierko A; Agrawal S; Stephans KL; Spratt DE; Hearn JW; Koontz BF; Lee WR; Michalski JM; Pisansky TM; Liauw SL; Abramowitz MC; Pollack A; Moghanaki D; Anscher MS; Den RB; Zietman AL; Stephenson AJ; Efstathiou JA
JAMA Oncol; 2018 May; 4(5):e175230. PubMed ID: 29372236
[TBL] [Abstract][Full Text] [Related]
9. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
[TBL] [Abstract][Full Text] [Related]
10. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
11. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience.
Yoshida T; Nakayama M; Suzuki O; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishiyama K; Nishimura K
Jpn J Clin Oncol; 2011 Aug; 41(8):1031-6. PubMed ID: 21693484
[TBL] [Abstract][Full Text] [Related]
12. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
[TBL] [Abstract][Full Text] [Related]
14. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors.
Brooks JP; Albert PS; Wilder RB; Gant DA; McLeod DG; Poggi MM
J Urol; 2005 Dec; 174(6):2204-8, discussion 2208. PubMed ID: 16280764
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy.
Song W; Jeon HG; Sung HH; Jeong BC; Seo SI; Jeon SS; Choi HY; Lee HM
Int J Urol; 2016 Jan; 23(1):56-61. PubMed ID: 26502086
[TBL] [Abstract][Full Text] [Related]
16. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen doubling time subsequent to radical prostatectomy is a predictor of outcome following salvage external beam radiation therapy: a single-centre experience.
Servoll E; Sæter T; Vlatkovic L; Nesland JM; Waaler G; Axcrona K
Scand J Urol; 2015 Jun; 49(3):218-23. PubMed ID: 25428750
[TBL] [Abstract][Full Text] [Related]
18. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ?
MacDonald OK; Schild SE; Vora S; Andrews PE; Ferrigni RG; Novicki DE; Swanson SK; Wong WW
Urology; 2004 Oct; 64(4):760-4. PubMed ID: 15491716
[TBL] [Abstract][Full Text] [Related]
19. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
20. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]